FDA Continues to Accelerate Development of Novel Therapies for COVID-19

by TLM


Yesterday the FDA issued a new COVID-19 update. Click here to read the press announcement.

What this means for you:

We have been monitoring this situation for our industry very closely and with the recent announcements and updates from the FDA, it is critical right now to follow Good Clinical Practices so that potential treatments can be fast-tracked.

Learn more about our GCP thoughts and other solutions we have developed over the last two decades of helping our industry navigate clinical trials in a way that makes sense to develop processes designed to avoid regulatory compliance issues.

The Compliance Insight Team